AIM IMMUNOTECH INC (AIM)

Company Profile

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 22 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Company Info

AIM IMMUNOTECH INC

2117 SW Highway 484

Ocala FLORIDA 34473

P: 13524487797

CEO: Thomas K. Equels

Employees: 22

Website: https://aimimmuno.com/